[HTML][HTML] Early myeloid-derived suppressor cells (HLA-DR−/lowCD33+CD16−) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host …
Journal of hematology & oncology, 2019•Springer
Introduction Myeloid-derived suppressor cells (MDSCs) are proposed to control graft-versus-
host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
However, the definition of human MDSCs has not yet reached consensus, and the
mechanism of MDSCs to control GVHD remains unclear. Methods Immature myeloid cells
(HLA-DR−/low CD33+ CD16−) were tested before and after granulocyte colony-stimulating
factor (G-CSF) administration in healthy donor and isolated for suppression assays and co …
host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
However, the definition of human MDSCs has not yet reached consensus, and the
mechanism of MDSCs to control GVHD remains unclear. Methods Immature myeloid cells
(HLA-DR−/low CD33+ CD16−) were tested before and after granulocyte colony-stimulating
factor (G-CSF) administration in healthy donor and isolated for suppression assays and co …
Introduction
Myeloid-derived suppressor cells (MDSCs) are proposed to control graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the definition of human MDSCs has not yet reached consensus, and the mechanism of MDSCs to control GVHD remains unclear.
Methods
Immature myeloid cells (HLA-DR−/lowCD33+CD16−) were tested before and after granulocyte colony-stimulating factor (G-CSF) administration in healthy donor and isolated for suppression assays and co-culture with T cells in vitro. Isolated cells were infused in humanized mice for a xenogeneic model of acute GVHD. One hundred allo-HSCT recipients were enrolled prospectively to assess the role of HLA-DR−/lowCD33+CD16− cells in grafts on the occurrence of acute GVHD.
Results
In the present study, G-CSF mobilized HLA-DR−/lowCD33+CD16− cells with immunosuppressive properties in donor peripheral blood. These cells contained more interleukin-10+ and transforming growth factor-beta (TGF-β)+ cells after G-CSF administration and inhibited the proliferation of autologous donor T cells in a TGF-β-dependent manner. Meanwhile, these immature myeloid cells promoted regulatory T cell expansion and induced Th2 differentiation. Importantly, these cells prevented acute GVHD in a humanized mouse model. Moreover, clinical cohort results showed that the number of HLA-DR−/lowCD33+CD16− cells in the donor graft was the only independent risk factor inversely correlated with the incidence of grade II–IV acute GVHD in the recipients (HR 0.388, 95% CI 0.158–0.954, p = 0.039).
Conclusion
HLA-DR−/lowCD33+CD16− cells represent functional MDSCs that may control acute GVHD in allo-HSCT.
Springer